Stemline Targeting cancer at its root
developing novel drugs that attack Cancer Stem Cells

SEC Filings

SEC Filings

Form Description Filing date View
DEF 14A

Official notification to shareholders of matters to be brought to a vote ("Proxy")

View HTML
DEFA14A

Additional proxy soliciting materials - definitive

View HTML
3

Initial filing by director officer or owner of more than ten percent.

View HTML
3

Initial filing by director officer or owner of more than ten percent.

View HTML
3

Initial filing by director officer or owner of more than ten percent.

View HTML
8-K

Report of unscheduled material events or corporate event

View HTML
8-K

Report of unscheduled material events or corporate event

View HTML
10-K

Annual report which provides a comprehensive overview of the company for the past year

EX-101.INS - XBRL INSTANCE DOCUMENT View HTML
424B5

Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3

View HTML
8-K

Report of unscheduled material events or corporate event

View HTML

Copyright Morningstar



Copyright 2018 - Stemline Therapeutics, Inc. All rights reserved